Read More Pharma Industry News Eli Lilly’s sofetabart mipitecan earns FDA Breakthrough Therapy status in platinum-resistant ovarian cancer Eli Lilly's sofetabart mipitecan receives FDA Breakthrough Therapy designation in platinum-resistant ovarian cancer. Find out what this means for the ADC space. bySrinathJanuary 21, 2026